Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

The anti-CD20 mAb rituximab has substantially improved the clinical outcome of patients with a wide range of B-cell malignancies. However, many patients relapse or fail to respond to rituximab, and thus there is intense investigation into the development of novel anti-CD20 mAbs with improved therape...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alduaij, Waleed, Ivanov, Andrei, Honeychurch, Jamie, Cheadle, Eleanor J., Potluri, Sandeep, Lim, Sean H., Shimada, Kazuyuki, Chan, Claude H. T., Tutt, Alison, Beers, Stephen A., Glennie, Martin J., Cragg, Mark S., Illidge, Tim M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2011
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3099571/
https://ncbi.nlm.nih.gov/pubmed/21378274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-07-296913
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares